FeesSafety
Pluang+

Bitcoin struggles near $76K amid Fed rate hike fears and weak technicals, with risk of drop to $72K.

Technical Signals
08 Nov 2026, 21:07 WIB
Coinpaper
View Source
Bearish
Bitcoin struggles near $76K amid Fed rate hike fears and weak technicals, with risk of drop to $72K.

Bitcoin is trading near $76,000 but faces pressure after last week's selloff and rising expectations of Federal Reserve rate hikes. The cryptocurrency's technical outlook remains weak, with resistance around $76,300 and $78,000, while support levels near $75,150 and $74,000 could be tested. A sustained drop below $74,000 might lead to a further decline toward $72,000, especially if US equities weaken. Additionally, significant outflows from US spot Bitcoin ETFs, including BlackRock's IBIT, add to recovery challenges. The upcoming US inflation report on November 10 is a key event that could influence Bitcoin's direction, as higher interest rates may dampen demand for speculative assets like Bitcoin.

Bitcoin price prediction is the subject, with Pluang market data providing context. As of Nov 09, 2026 01:02 WIB, out of 50 major cryptocurrencies priced on Pluang, 8 rose and 40 fell. Notable movers include THETA at Rp2.532 with a 1-day change of -4.09%, GRT at Rp333 down 4.07%, and ENJ at Rp410 down 3.86%.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
4 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
4 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
4 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
4 hours ago
Bitcoin Cash drops 4.5%, deepening weekly losses over 13% as Bitcoin holds steady near $75,800

Bitcoin Cash drops 4.5%, deepening weekly losses over 13% as Bitcoin holds steady near $75,800

Bitcoin Cash (BCH) fell about 4.5% on November 8, extending its weekly losses beyond 13%, while Bitcoin remained stable near $75,800. BCH's price dropped below key support levels around $250 and tested $244, signaling weaker demand compared to Bitcoi...

Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App